Investigational drug · Phase 2
ACR-2316
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Specific Advanced Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ACR-2316"
First trial start
2024
Oct 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACR-2316", any sponsor or status.
Conditions studied
As listed on its trial records.
- Specific Advanced Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ACR-2316" as an intervention, largest first.
- Study of ACR-2316 in Specific Advanced Solid TumorsPivotal-lookingRecruiting
Acrivon TherapeuticsIndustry
NCT06667141 · 100 participants (planned) · Start Oct 8, 2024 · Primary completion Aug 12, 2027
Drug: ACR-2316 · For: Specific Advanced Solid Tumors
Sites: Phoenix, Arizona; Beverly Hills, California; Newport Beach, California · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.